title: Dermatologic adverse events: golimumab, friend or foe?
abstract: Golimumab is a fully human anti-TNF-alpha blocker that has demonstrated its efficacy in the treatment of numerous kinds of diseases. Although it is generally safe and well tolerated, various adverse events have been reported. The present aim is to improve the understanding of dermatologic adverse events associated with golimumab following a search of various scientific databases. This systematic review and meta-analysis shows that golimumab is associated neither with severe injection-site reactions nor with injection-site erythema. We found no significant lupus-like syndromes, and no significant skin squamous cell carcinoma. We further suggest systematic dermatologic monitoring in clinical practice during golimumab therapy. Subsequent research should employ a larger cohort of patients to ensure clear and significant future conclusions.
authors.affiliation: Laboratory of Biochemistry, Research Unit 02/UR/09-01, Higher Institute of Biotechnology, BP 74, Avenue Tahar Haddad, Monastir 5000, Tunisia. ines.zidi@techemail.com
authors.forename: I
authors.initials: I
authors.lastname: Zidi
authors.forename: A
authors.initials: A
authors.lastname: Bartegi
authors.forename: Amor N
authors.initials: AN
authors.lastname: Ben
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology*; D006801:Humans; D012867:Skin / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab